1-萘酚哌嗪盐酸盐 | 104113-71-5

• 物质功能分类: 医药中间体 - 杂环化合物 - 哌嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-萘酚哌嗪盐酸盐
• 中文别名: 1-(1-萘基)哌嗪盐酸盐；1-(1-萘)哌嗪盐酸盐
• 英文名称: 1-(1-naphthyl)piperazine hydrochloride
• 英文别名: 1-Naphtylpiperazine hydrochloride；1-Naphthalen-1-ylpiperazin-4-ium;chloride
• CAS: 104113-71-5
• 化学式: C₁₄H₁₆N₂*ClH
• 分子量: 248.755
• InChiKey: ZYVYPNZFOCZLEM-UHFFFAOYSA-N

物化性质

• 熔点：
  235-237 °C
• 溶解度：
  可溶于水中

计算性质

• 辛醇/水分配系数(LogP)：
  2.67
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  15.3
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• WGK Germany：
  3
• 海关编码：
  2933599090

制备方法与用途

应用1-(1-萘基)哌嗪盐酸盐可作为有机合成中间体和医药中间体，主要应用于实验室研发及化工生产过程。

反应信息

• 作为反应物：
  描述：

  1-萘酚哌嗪盐酸盐 在 potassium carbonate 、 N,N'-羰基二咪唑 、 肼 作用下， 以 四氢呋喃 、 乙醇 、 丙酮 为溶剂， 反应 5.0h， 生成 N-(4-(4-(naphthalen-1-yl)piperazin-1-yl)butyl)benzofuran-2-carboxamide oxalic acid
  参考文献：
  名称：

  High Affinity Dopamine D₃ Receptor (D₃R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D₃R Knockout Mice

  摘要：

  The dopamine D-3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders. Several D3R-selective antagonists are effective in animal models of drug abuse, especially in models of relapse. Nevertheless, poor bioavailability, metabolic instability, and/or predicted toxicity have impeded success in translating these drug candidates to clinical use. Herein, we report a series of D3R-selective 4-phenylpiperazines with improved metabolic stability. A subset of these compounds was evaluated for D3R functional efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with D3R has been observed. Several high affinity D3R antagonists, including compounds 16 (K-i = 0.12 nM) and 32 (K-i = 0.35 nM), showed improved metabolic stability compared to the parent compound, PG648 (6). Notably, 16 and the classic D3R antagonist SB277011A (2) were effective in reducing selfadministration of heroin in wild-type but not D3R knockout mice.

  DOI：

  10.1021/acs.jmedchem.5b00776
• 作为产物：
  描述：

  二(2-氯乙基)胺盐酸盐 、 1-萘胺 在 potassium carbonate 、 盐酸 作用下， 以 二乙二醇二甲醚 、 异丙醇 、 丙酮 为溶剂， 反应 48.0h， 以57%的产率得到1-萘酚哌嗪盐酸盐
  参考文献：
  名称：

  High Affinity Dopamine D₃ Receptor (D₃R)-Selective Antagonists Attenuate Heroin Self-Administration in Wild-Type but not D₃R Knockout Mice

  摘要：

  The dopamine D-3 receptor (D3R) is a promising target for the development of pharmacotherapeutics to treat substance use disorders. Several D3R-selective antagonists are effective in animal models of drug abuse, especially in models of relapse. Nevertheless, poor bioavailability, metabolic instability, and/or predicted toxicity have impeded success in translating these drug candidates to clinical use. Herein, we report a series of D3R-selective 4-phenylpiperazines with improved metabolic stability. A subset of these compounds was evaluated for D3R functional efficacy and off-target binding at selected 5-HT receptor subtypes, where significant overlap in SAR with D3R has been observed. Several high affinity D3R antagonists, including compounds 16 (K-i = 0.12 nM) and 32 (K-i = 0.35 nM), showed improved metabolic stability compared to the parent compound, PG648 (6). Notably, 16 and the classic D3R antagonist SB277011A (2) were effective in reducing selfadministration of heroin in wild-type but not D3R knockout mice.

  DOI：

  10.1021/acs.jmedchem.5b00776

文献信息

• [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
  申请人：Clark D. Jerry

  公开号：US20050043309A1

  公开（公告）日：2005-02-24

  This invention relates to compounds of the formula 1 wherein G, D, A, Z, Q, X, Y, R 1 , and R 4 through R 7 are defined as in the specification, processes for preparing the same and intermediates used in making the same, and pharmaceutical compositions containing such compounds and their use in the treatment of central nervous system disorders and other disorders.

  这项发明涉及公式1的化合物 其中G、D、A、Z、Q、X、Y、R 1 和R 4 至R 7 的定义如规范中所述，制备这些化合物的方法以及用于制备这些化合物的中间体，以及含有这些化合物的药物组合物及其在治疗中枢神经系统疾病和其他疾病中的用途。
• Use of ER selective NF-kB inhibitors for the treatment of sepsis
  申请人：Caggiano J. Thomas

  公开号：US20050256132A1

  公开（公告）日：2005-11-17

  The present invention provides methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome by modulating NF-κB transcription with ligands that interact with the estrogen receptor, preferably in the absence of classic estrogenic activity. Other aspects of the invention relate to methods for treating sepsis, systemic inflammatory response syndrome, severe sepsis, septic shock, and multiple organ dysfunction syndrome that comprise administering to a patient suffering therefrom an effective amount of a compound of Formula I:

  本发明提供了通过调节与雌激素受体相互作用的配体来调节NF-κB转录，从而治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，优选在无典型雌激素活性的情况下进行。本发明的其他方面涉及治疗脓毒症、全身性炎症反应综合征、严重脓毒症、脓毒性休克和多器官功能障碍综合征的方法，包括向患有此类病症的患者施用有效量的式I化合物：
• [EN] NEW ANTIBACTERIAL COMPOUNDS<br/>[FR] NOUVEAUX COMPOSÉS ANTIBACTÉRIENS
  申请人：ACRAF

  公开号：WO2016096631A1

  公开（公告）日：2016-06-23

  The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

  本发明涉及新型的抗菌化合物、含有它们的药物组合物以及它们作为抗菌剂的应用。
• Method of treating tourette's syndrome and obsessive compulsive disorder
  申请人：Pfizer Inc.

  公开号：US06127373A1

  公开（公告）日：2000-10-03

  A method for treating Tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal, including a human, comprising administering to said mammal an effective amount of a compound of the formula ##STR1## or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

  在哺乳动物，包括人类中，治疗抽动症、强迫症、慢性运动或发声抽动障碍的方法，包括向该哺乳动物施用公式##STR1##中的化合物或其药用可接受的酸盐的有效量，其中n、X、Y和Ar如上所定义。
• Method of treating psychiatric conditions
  申请人：Pfizer Inc

  公开号：US06245766B1

  公开（公告）日：2001-06-12

  A method for treating a psychiatic condition or disorder selected from anxiety disorders such as panic disorder, posttraumatic stress disorder and phobias, psychotic episodes of anxiety, anxiety associated with psychosis, psychotic mood disorders such as severe major depressive disorder and mood disorders associated with psychotic disorders such as acute mania or depression associated with bipolar disorder, schizophrenia, behavioral manifestations of mental retardation, conduct disorder or autistic disorder, dementias such as dementias of the Alzheimer's type, and dyskinesias such as drug induced and neurodegeneration based dyskinesias in a mammal, including a human, comprising administering to said mammal a pharmaceutically effective amount of a compound of the formula or a pharmaceutically acceptable acid addition salt thereof, wherein n, X, Y and Ar are as defined above.

  一种用于治疗精神疾病或障碍的方法，所述精神疾病或障碍包括恐慌症、创伤后应激障碍和恐惧症等焦虑障碍，焦虑的精神病性发作，与精神病相关的焦虑，严重的重性抑郁障碍等精神情绪障碍，以及急性躁狂或与双相情感障碍相关的抑郁等精神障碍，如双相情感障碍、精神发育迟滞的行为表现、行为障碍或自闭症障碍、阿尔茨海默病型痴呆症和药物诱导的运动障碍以及基于神经退行性的运动障碍等运动障碍，包括人类在内的哺乳动物，包括向所述哺乳动物投予上述化合物的药效有效量或其药学上可接受的酸盐加合物，其中n、X、Y和Ar如上所定义。